WallStSmart

Johnson & Johnson (JNJ)vsNexalin Technology Inc. (NXL)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 45742668% more annual revenue ($99.33B vs $217,160). JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 54/100 (C-).

JNJ

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 8.5Value: 3.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64

NXL

Avoid

25

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 3.0
Piotroski: 4/9Altman Z: -30.42

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$682.52B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
26.6%8/10

Strong operational efficiency at 26.6%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

NXL1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Areas to Watch

JNJ4 concerns · Avg: 2.8/10
Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
43.0x2/10

Premium valuation, high expectations priced in

NXL4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.54M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-319.7%2/10

ROE of -319.7% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.

Bull Case : NXL

The strongest argument for NXL centers on Price/Book.

Bear Case : JNJ

The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.

Bear Case : NXL

The primary concerns for NXL are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 4.66 is elevated, increasing financial risk.

Key Dynamics to Monitor

JNJ profiles as a mature stock while NXL is a value play — different risk/reward profiles.

NXL carries more volatility with a beta of 4.34 — expect wider price swings.

JNJ is growing revenue faster at 5.9% — sustainability is the question.

JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (54/100 vs 25/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Nexalin Technology Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Nexalin Technology Inc. is a pioneering medical technology firm dedicated to transforming the treatment of neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. By offering non-invasive solutions for prevalent mental health issues such as anxiety, depression, and substance addiction, the company underscores its commitment to improving patient outcomes and advancing accessible mental health care. With a robust research background and a strategic focus on tapping into the rising demand for innovative healthcare solutions, Nexalin is well-positioned for growth in the rapidly expanding digital health sector, presenting a compelling investment opportunity for institutional investors.

Want to dig deeper into these stocks?